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80%. Persistence was deﬁned as the number of days on thera-
pies until the ﬁrst 30-day gap. Propensity-score weighted logistic
regression and proportional hazard models were used to adjust
for baseline demographics, copay and pharmacy utilization vari-
ables. RESULTS: At baseline, across the SPAA and 2PAA groups
(N = 1,530), mean age was 62 years, 49% were female, 10%
utilized coronary vasodilators, 28% utilized anti-diabetics; mean
number of other baseline medications was 7. These characteris-
tics varied among all cohorts. Patients receiving SPAA were
nearly twice as likely to achieve adherence, and approximately
20% less likely to discontinue therapy at all doses; compared to
the European dose equivalents, the adjusted odds ratio of achiev-
ing adherence was 1.83 (95% conﬁdence interval (CI) 1.60–2.10,
P < 0.0001) and the discontinuation hazard ratio was 0.83 (CI
0.74–0.93, P = 0.0012). CONCLUSION: Single-pill amlodipine/
atorvastatin was associated with greater adherence and less dis-
continuation vs. 2-pill amlodipine and atorvastatin, at low, high,
and European doses of both medications.
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OBJECTIVES: Although guidelines recommend ﬁrst-line combi-
nation therapy for patients with severe hypertension, no quanti-
tative beneﬁt/risk estimate has been provided. The objective of
this study was to estimate these potential long-term beneﬁts and
risks based on results of a registrational clinical program.
METHODS: Results from a clinical study in severe hypertension
(diastolic blood pressure > = 110 mmHg) were used to project
beneﬁts and risks of irbesartan/hydrochlorothiazide (I/H) vs.
irbesartan monotherapy (I). In the randomized, controlled,
double-blind, 7-week trial (n = 695), initial I/H reduced exposure
to severe blood pressure (BP) levels (p = 0.0003) and provided an
additional BP reduction of approximately 10/5 mmHg (systolic/
diastolic) compared to I (p < 0.0001 for each parameter) with
similar safety. Beneﬁt was extrapolated by using cardiovascular
risks described in World Health Organization Guidelines. The BP
difference between I/H and I was applied conservatively to a time
frame of 0.1 to 0.8 years, as physicians in actual practice may
add adjunctive therapy after the initial prescription. The poten-
tial for serious adverse events from the use of I/H were estimated
based on post-marketing surveillance data (10 million patient
years of exposure to I/H) and literature review. RESULTS: A
population of 100,000 patients with severe hypertension is at
risk for between 2,500 and 10,000 cardiovascular events in one
year. Initial treatment with I/H instead of I is projected to prevent
between 100 and 1,000 events in one year. No signal of poten-
tially serious adverse events exists for I/H compared to I in
post-marketing data, but an estimate of between 0 to 3 such
events may be considered. CONCLUSION: The estimated
beneﬁt/risk of ﬁrst-line I/H is highly favorable, even when applied
to a short time horizon. This is because cardiovascular risk is the
greatest issue for the patient with severe hypertension. Earlier
and more extensive use of combination therapy can improve
public health.
PODIUM SESSION I: ECONOMICS OF DIABETES
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OBJECTIVES: A ﬁxed-effects (weighted average) meta-analysis
of three clinical trials showed the short-term therapy beneﬁts of
treating type 1 diabetic patients (mean age 40.3 years, duration
of diabetes 16.3 years, HbA1c 8.3%, BMI 25.2 kg.m-2) with
insulin detemir (IDet) versus neutral protamine Hagedorn (NPH)
insulin as the basal component of basal-bolus therapy when used
in combination with either insulin aspart (IAsp) or human
soluble insulin (HSI). METHODS: A published validated diabe-
tes model was used to estimate the long-term cumulative inci-
dence of complications, life expectancy (LE), quality-adjusted life
expectancy (QALE) and lifetime costs for IDet versus NPH regi-
mens. The short-term treatment effects (0.13% points lower
HbA1c, a 4% decrease in hypoglycaemic events and lower body
mass index 0.21 kg.m-2) observed in the meta-analyses were
projected using progression data derived from landmark clinical
and epidemiological studies. The costs of treating complications
in the German setting were taken from published sources and
total direct costs (complications + treatment costs) for each arm
were projected over patient lifetimes. Both costs and clinical
outcomes were discounted at 5% annually. RESULTS: The IDet
arm was associated with an increase in life expectancy, compared
to NPH, of 0.052 years (12.270  0.130 versus 12.218  0.121
years) with a resulting gain in QALE of 0.144 quality-adjusted
life years (QALYs) (6.23  0.07 versus 6.09  0.06 QALYs)
due to a reduction in diabetes-related complications. Increased
treatment costs for IDet resulted in greater total lifetime
costs per patient than with NPH (€91,960  2333 versus
€89,367  2183, difference €2,593), leading to an incremental
cost-effectiveness ratio of €18,070 per QALY gained. CONCLU-
SION: Short-term improvements seen with IDet versus NPH in
basal-bolus therapy were projected to show improvements in
both life expectancy and quality-adjusted life expectancy with a
cost-effectiveness ratio which fell well within the range usually
considered to represent value for money (<€50,000 per QALY
gained).
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OBJECTIVES: The aim of this analysis was to evaluate the
cost-utility of switching type 2 diabetes patients receiving human
soluble insulin (HSI) to rapid-acting insulin aspart (IAsp,
NovoRapid), with or without oral hypoglycemic agents, in the
German setting. METHODS: The CORE Diabetes Model, a
published and validated computer simulation model, was used to
project long-term clinical and economic outcomes associated
with IAsp and HSI treatment effects. The model is based on 15
semi-Markov sub-models representing the most important acute
and chronic diabetes-related complications including eye, renal
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and cardiovascular disease amongst others. Treatment effects and
cohort characteristics (mean age 63.1 years, diabetes duration
12.8 years, HbA1c 8.17%, BMI 30.3 kg/m2) were based on the
German cohort of the PREDICTIVE (Predictable Results and
Experience in Diabetes through Intensiﬁcation and Control to
Target: an International Variability Evaluation) study. Direct
medical costs were derived from published sources and expressed
in 2006 Euro (€) values. Projections were made over a 35-year
time horizon. Future costs and clinical beneﬁts were discounted
at 3.5% annually. Sensitivity analyses were performed.
RESULTS: Treatment with IAsp was projected to improve
quality-adjusted life expectancy by approximately 0.10 quality-
adjusted life years (QALYs) (6.06  0.09 versus 5.96  0.09
QALYs). Increased treatment costs with IAsp were partially
offset by cost savings due to reductions in the cumulative inci-
dence of diabetes-related complications. Over patient lifetimes,
mean direct medical costs were projected to increase by
approximately €1,274 per patient with IAsp versus HSI
(€45,423  1,354 versus €44,149  1,391). This resulted in
an incremental cost-utility ratio of €13,305 per QALY gained.
CONCLUSION: Over patient lifetimes, IAsp treatment was
projected to result in fewer diabetes-related complications
and improved quality-adjusted life expectancy compared to
HSI. Based on currently accepted willingness-to-pay limits, IAsp
would represent good value for money in the German setting.
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OBJECTIVES: An objective of the INSTIGATE study is to
describe the resource utilisation associated with care for type 2
diabetes in the 6 months before and after insulin initiation. This
abstract presents data from patients enrolled in Germany
and UK. METHODS: INSTIGATE is an ongoing prospective
European observational study investigating patients with type 2
diabetes who have initiated insulin during usual care. Data on
resource use for diabetes was collected at baseline retrospectively
for the 6 months prior to initiating insulin and at 3 and 6 months
following insulin initiation. RESULTS: In all, 509 patients were
enrolled in Germany and UK. 6 month follow-up data was
collected from 457 patients. The following changes in health care
professional consultations were observed in the 6 months before
and after insulin initiation: The % of patients with a visit to a
primary care doctor declined from 93.4% to 83.7% in Germany,
and in the UK from 79.4% to 48.2%. Visits to specialist nurses
increased in Germany from 52.3% to 91.4%, and in the UK from
77.5% to 81.7 % of patients. In both countries the % of patients
having phone calls with a specialist nurse increased; from 11.7%
to 50.6% in Germany and from 21.3% to 75.9% in UK. The %
of patients using a blood glucose monitor and the median weekly
number of test strips used increased in both countries, most
notably in Germany from 76.6% of patients testing 4 times a
week before insulin initiation to 99.6% of patients testing 21
times per week 6 months after insulin initiation. CONCLU-
SION: The type of health care professionals visited and nature of
the consultations changed in both countries following insulin
initiation; the % of patients having visits to primary care pro-
viders decreased and the % of patients having visits and phone
calls to specialist nurses increased.
ED4
THE RELATIVE COST EFFECTIVENESS OF SWITCHINGTO
INSULIN GLARGINEVERSUS NPH INSULIN IN INSULIN NAIVE
AND NON INSULIN NAIVETYPE 2 DIABETES PATIENTS
USING UK REAL LIFE DATA
McEwan P1, Mehin N2,Tetlow AP3, Sharplin P3
1Cardiff University, Cardiff, South Glamorgan, UK, 2sanoﬁ-aventis, Paris,
France, 3Cardiff Research Consortium, Cardiff, South Glamorgan, UK
OBJECTIVES: This study, conducted in Type 2 diabetes mellitus
(T2DM), evaluated the cost utility of glargine versus NPH in
previously insulin naïve (IN) and non insulin naïve (NIN)
patients switching from NPH to insulin glargine in the UK using
observational data. The study assessed the combined effect of
HbA1c and hypoglycaemia reduction. METHODS: A discrete
event life time simulation based on UKPDS 68 was adapted to
include the effects of HbA1c and hypoglycaemia reduction using
published meta-regression results from 11 randomised clinical
trials. Direct costs and health utility (EQ5D) were derived from
published sources and the HODaR database respectively; costs
and beneﬁts were discounted at 3.5%. This model used the
demographic and efﬁcacy proﬁles of T2DM patients who were
IN or NIN who switched from NPH to glargine identiﬁed via the
THIN database. Analysis was conducted on 1,496 and 174 IN
and NIN patients respectively; the primary outcome measure was
Hba1c change. As hypoglycaemia was not directly collected from
the THIN database, sensitivity analysis was performed taking
into account HbA1c beneﬁt only. RESULTS: The mean age and
duration of diabetes at switch was 63 years and 7.5 years (IN)
and 70 years and 10.2 years (NIN) respectively. After adjustment
for baseline proﬁles IN patients starting glargine showed a sig-
niﬁcant reduction in HbA1c of 0.21% (p = 0.029) 12 months
post initiation versus NPH. For NIN patients switching from
NPH to glargine the adjusted HbA1c reduction was 0.46%
(p = 0.0093). The cost per QALY for a simulated cohort of
10,000 patients was £5,806 and £3,415 for IN and NIN patients.
In sensitivity analysis considering an HbA1c reduction only the
cost per QALY was £18,179 and £7,973 for IN and NIN patients
respectively. CONCLUSION: Based on real life observational
data, in both IN and NIN patients T2DM patients, glargine is
cost-effective compared to NPH.
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OBJECTIVES: This study tested a method to measure the vari-
ability of data among countries, and to assess the generalisability
of cost evaluation results. METHODS: The ﬁrst step of the
method consisted in identifying, within cost evaluations, all the
factors potentially responsible for variability among locations.
The second step consisted in selecting, among all potential trans-
ferability factors, the ﬁnal transferability factors which generated
variability, impacted on outcomes of economic evaluation, and
were both measurable and distinguishable from other factors.
The third step was the identiﬁcation of transferability areas
as sets of homogeneous ﬁnal transferability factors. Both the
Euclidean metric and Principal Components Analysis were used
in the fourth step to explore the generalisability of the results.
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